HUNTSMAN RONALD KIRK (Chairman & CEO) purchased 77.4% of their position (12K shares) of VIVOS THERAPEUTICS, INC. on the open market
Open‑market purchase worth $23.6K — a major conviction buy. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 6/3/2022ACC: 0001493152-22-015773
DirectorOfficer10% Owner· Chairman & CEO
Since Dec 2020
+12K
Net shares
Net buyer
$23.6K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
12K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+8K
Price / share
$2.03
Trade value
$16.24K
% of position
51.6%
5/31/2022
15.50K→23.50K
Common Stock
Direct
Shares
+4K
Price / share
$1.83
Trade value
$7.32K
% of position
17.0%
6/1/2022
23.50K→27.50K
Total
Net shares
+12K
Net value
$23.56K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/31/2022 | P · Purchase | +8K | $2.03 | $16.24K | 51.6% | 15.50K | 23.50K |
| Common Stock Direct | 6/1/2022 | P · Purchase | +4K | $1.83 | $7.32K | 17.0% | 23.50K | 27.50K |
| Total | +12K | $23.56K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned1.74M
Total
1.74M indirect1.74M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 1.74M | Indirect |
| Total | 1.74M | 1.74M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported